MoonLake Immunotherapeutics, (MLTX): Price and Financial Metrics

MoonLake Immunotherapeutics, (MLTX): $50.23

0.02 (+0.04%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

Add MLTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#295 of 365

in industry

MLTX Price/Volume Stats

Current price $50.23 52-week high $64.98
Prev. close $50.21 52-week low $17.82
Day low $48.70 Volume 1,172,700
Day high $52.92 Avg. volume 487,254
50-day MA $53.56 Dividend yield N/A
200-day MA $52.48 Market Cap 3.21B

MLTX Stock Price Chart Interactive Chart >


MoonLake Immunotherapeutics, (MLTX) Company Bio


MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.


MLTX Latest News Stream


Event/Time News Detail
Loading, please wait...

MLTX Latest Social Stream


Loading social stream, please wait...

View Full MLTX Social Stream

Latest MLTX News From Around the Web

Below are the latest news stories about MOONLAKE IMMUNOTHERAPEUTICS that investors may wish to consider to help them evaluate MLTX as an investment opportunity.

MoonLake Immunotherapeutics (MLTX) Posts Q3 2023 Results: Clinical Progress Amid Controlled Expenses

MLTX Advances in Clinical Trials with Strong Cash Position

Yahoo | November 14, 2023

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for hidradenitis suppurativa Presented positive 12-week data from the global Phase 2 MIRA clinical trial for sonelokimab in hidradenitis suppurativa at a late-breaking session during the European Academy of Dermat

Yahoo | November 14, 2023

Why Former Highflier MoonLake Plummeted 29% After A Recent Run

MoonLake Immunotherapeutics reported mixed test results for its psoriatic arthritis treatment on Monday, and top-rated MLTX stock crashed.

Yahoo | November 6, 2023

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of potential best-in-class profilePrimary endpoint ACR50 met with up to 47% (p<0.01 versus placebo) of patients on sonelokimab achieving ACR50 as early as week 12All key secondary endpoints met including up to 77% (p<0.001 versus placebo)

Yahoo | November 5, 2023

12 Best Performing NASDAQ Stocks in 2023

In this piece, we will take a look at the 12 best performing NASDAQ stocks in 2023. If you want to skip our introduction to the NASDAQ’s performance this year and the broader stock market, then read 5 Best Performing NASDAQ Stocks in 2023. The NASDAQ has been one of the best performing stock indexes […]

Yahoo | October 26, 2023

Read More 'MLTX' Stories Here

MLTX Price Returns

1-mo -11.58%
3-mo -16.82%
6-mo -11.88%
1-year 129.89%
3-year 392.45%
5-year N/A
YTD -16.82%
2023 475.14%
2022 6.17%
2021 -13.02%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!